NCT02852655View on ClinicalTrials.gov

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

June 2, 2022

Study Completion Date

January 31, 2026

Conditions
Brain Cancer
Interventions
DRUG

MK-3475

Trial Locations (7)

10065

Memorial Sloan-Kettering Cancer, New York

77030

UT, MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, Salt Lake City

90095

University of California, Los Angeles, Los Angeles

94143-0372

University of California, San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER